MEDICAL RESOURCES

Evobrutinib 
BTK inhibitor

Status

Evobrutinib is a BTK inhibitor currently under investigation in clinical trials.

MAVENCLAD, Rebif, Rebif Rebidose and MS LifeLines are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. 

Action SVG
Action SVG
Action SVG
eMedI Chat
Close
After your vist, Please answer a few questions to help us improve?
Survey
Please click on icon to provide survey...